Researchers presented data from a study that aimed to evaluate pentraxin-3 (PTX3) as a circulating marker of inflammation in patients with suspected myocarditis.
Mitochondrial disorders have shown phenotypic and genetic heterogeneity; cytochrome c oxidase assembly protein COX11 is an assembly factor that works as a copper chaperone. Previous findings have unveiled that COX11 knockdown causes a reduction in ATP production in vitro.
There is still a percentage of patients with multiple myeloma (MM) who do not respond to initial therapy, and they are considered as refractory MM patients. There is a need for novel biomarkers of treatment response in refractory MM.
Atrial fibrillation (AF) is a very common diagnosed arrhythmia and catheter ablation is an effective treatment, but recurrence occurs after catheter ablation and remains a medical challenge. MicroRNAs can be easily detected in the circulation, and they are epigenetic regulators in many biological processes; their usefulness as biomarkers of risk stratification in patients with AF was investigated.
Researchers from University Hospital Bonn presented data from a study that aimed to evaluate the significance of serum levels of the endoplasmic-reticulum-stress chaperone GRP78 in patients undergoing coronary angiography for suspected coronary artery disease (CAD).
The crosstalk between immune cells and multiple myeloma (MM) cells is an important determinant of MM progression, but the mechanisms behind this have not been fully defined.
There is a lack of biomarkers for disease activity in aortic stenosis (AS). On the other hand, citrullination is involved in many chronic inflammatory processes and citrullinated proteins have been found within atherosclerotic plaque.
Target ALS Foundation Inc. and the Alzheimer's Drug Discovery Foundation LLC (ADDF) have announced the first four award recipients in a new initiative to identify and develop biomarkers for neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD).
The prognostic role of complement inhibitor CSMD1 was assessed in 1,507 patients with glioma from three different datasets. Results of the bioinformatical analysis suggested that high expression of CSMD1 was associated with increased overall survival and disease-free survival, as well as lower tumor grade.